Key Takeaways
Key Takeaways
- Immunotherapy works by activating or enhancing the immune system’s natural ability to recognize and attack cancer cells.
- Several distinct types of immunotherapy exist, including checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines.
- Unlike chemotherapy, immunotherapy generally targets cancer cells more selectively, often resulting in a different side effect profile.
- Not every patient is a suitable candidate; eligibility depends on cancer type, biomarkers, and overall health status.
- Long-term responses are possible in some patients, with durable remissions reported across multiple cancer types.
How Immunotherapy Works Against Cancer Cells
The immune system continuously monitors the body for abnormal cells, using specialized proteins and immune cells to identify and eliminate threats. Cancer cells, however, have developed sophisticated strategies to evade detection — including masking surface proteins, producing immunosuppressive signals, and exploiting natural regulatory checkpoints that normally prevent the immune system from attacking healthy tissue.
Immunotherapy works by interfering with these evasion mechanisms, effectively lifting the “brakes” that cancer cells apply to immune responses. Checkpoint inhibitor drugs, for example, block proteins such as PD-1, PD-L1, or CTLA-4, which cancer cells exploit to remain invisible to T-cells. Once these checkpoints are blocked, T-cells can recognize and destroy tumor cells more effectively.
Some immunotherapy approaches go further by actively engineering immune cells outside the body before reinfusing them. In adoptive cell therapies, a patient’s T-cells are extracted, genetically modified to better recognize specific tumor antigens, and then returned to the body in far greater numbers. This approach essentially reprograms the immune system to treat cancer as a high-priority target rather than an undetected invader.
Types of Cancer Immunotherapy Treatments
The landscape of types of cancer immunotherapy treatments has expanded considerably, offering oncologists multiple strategies depending on cancer type, stage, and patient-specific factors. Each category works through a distinct biological mechanism, which is why different patients may respond to different approaches.
Checkpoint inhibitors are currently among the most widely used immunotherapy agents, with approvals across melanoma, non-small cell lung cancer, bladder cancer, and several other tumor types. Monoclonal antibodies represent another major class; these lab-engineered proteins bind to specific antigens on cancer cells, marking them for destruction or directly blocking growth signals. Cancer vaccines — both preventive, such as the HPV vaccine, and therapeutic — stimulate the immune system to recognize tumor-specific proteins.
Cytokine therapies use naturally occurring immune signaling molecules such as interleukins and interferons to amplify overall immune activity. CAR-T (chimeric antigen receptor T-cell) therapy, approved for certain blood cancers, involves genetically reprogramming a patient’s own T-cells to carry synthetic receptors that lock onto cancer cells. According to the National Cancer Institute, CAR-T therapies have produced complete remissions in some patients with relapsed or refractory leukemias who had exhausted other options.
- Checkpoint inhibitors: Block PD-1, PD-L1, or CTLA-4 proteins to restore T-cell activity against tumors.
- Monoclonal antibodies: Target specific cancer cell proteins to flag them for immune destruction.
- CAR-T cell therapy: Genetically engineered T-cells designed to seek and destroy specific cancer antigens.
- Cancer vaccines: Stimulate the immune system to recognize and attack tumor-associated proteins.
- Cytokine therapy: Uses immune signaling molecules to boost overall immune system activity.
Immunotherapy vs Chemotherapy: Key Differences and Effectiveness
Understanding the distinction between immunotherapy and chemotherapy is essential for patients navigating treatment decisions. Chemotherapy works by targeting rapidly dividing cells throughout the body, which is effective against many tumors but also damages healthy fast-dividing cells — such as those in hair follicles, the digestive tract, and bone marrow — producing well-known side effects like hair loss, nausea, and immunosuppression.
Immunotherapy, by contrast, does not directly attack cells based on division rate. Instead, it modifies immune system behavior, enabling it to distinguish cancer cells from healthy tissue with greater precision. This selectivity means the side effect profile differs significantly, though it is not necessarily milder in all cases. Immune-related adverse events can affect any organ system and occasionally become severe.
In terms of effectiveness, the comparison depends heavily on cancer type. The following table summarizes key differences between these two treatment modalities:
| Feature | Immunotherapy | Chemotherapy |
|---|---|---|
| Mechanism | Activates or modifies the immune system | Directly kills rapidly dividing cells |
| Selectivity | Generally more targeted to cancer cells | Affects all fast-dividing cells |
| Common side effects | Immune-related inflammation, fatigue, rash | Hair loss, nausea, bone marrow suppression |
| Duration of response | Can produce durable, long-lasting remissions | Responses often tied to active treatment cycles |
| Suitable cancers | Melanoma, lung, bladder, blood cancers, others | Broad spectrum across many cancer types |
The effectiveness of immunotherapy varies substantially by cancer type and individual patient biology. Research published by the American Cancer Society indicates that checkpoint inhibitors have improved five-year survival rates in metastatic melanoma from under 10% to approximately 40–50% in eligible patients. However, across all cancer types, only a subset of patients — typically those whose tumors express certain biomarkers — achieve major responses. Combination strategies, pairing immunotherapy with chemotherapy or targeted therapy, are increasingly used to improve outcomes.
Immunotherapy Side Effects and Who Is a Good Candidate
Immunotherapy side effects differ from those associated with traditional cancer treatments because they arise from immune system overactivation rather than direct tissue damage. When the immune system is stimulated broadly, it can begin attacking healthy organs, leading to a range of immune-related adverse events (irAEs). Common presentations include fatigue, skin rashes, diarrhea, and inflammation of the lungs (pneumonitis), liver (hepatitis), or endocrine glands.
Most side effects are manageable when caught early, and oncology teams routinely monitor patients for early warning signs throughout treatment. In more serious cases, treatment may need to be paused and corticosteroids administered to suppress the overactive immune response. Patients are advised to report any new or worsening symptoms promptly, as some irAEs can escalate quickly if not addressed.
Determining who is a good candidate for immunotherapy requires evaluating several clinical factors. Oncologists typically review tumor biomarkers such as PD-L1 expression levels, tumor mutational burden (TMB), and microsatellite instability (MSI) status. High TMB and MSI-high tumors tend to respond particularly well to checkpoint inhibitors. A patient’s overall immune function, existing autoimmune conditions, organ health, and prior treatment history also influence candidacy.
Patients with pre-existing autoimmune diseases — such as lupus, rheumatoid arthritis, or inflammatory bowel disease — require careful assessment, as immunotherapy can trigger flares of these conditions. Similarly, individuals on long-term immunosuppressive medications may not achieve the expected immune activation. Genetic and molecular profiling of the tumor has become a standard step in determining whether immunotherapy is likely to be beneficial, reflecting a broader shift toward precision oncology.
Immunotherapy FAQs
Some patients treated with immunotherapy achieve durable, long-lasting remissions that persist for years after treatment ends — particularly in melanoma and certain lung cancers. Whether this constitutes a cure depends on the individual case, cancer type, and ongoing monitoring. Oncologists use the term “complete response” when no detectable cancer remains, but long-term follow-up is always required. Results vary significantly based on tumor biology and patient health.
Immunotherapy is not universally effective across all cancers. It has demonstrated strong results in melanoma, non-small cell lung cancer, bladder cancer, kidney cancer, and several blood cancers. Other tumor types — including most pancreatic and colorectal cancers without MSI-high status — respond less reliably. Biomarker testing, including PD-L1 expression and tumor mutational burden, is essential to determine whether a specific patient’s cancer is likely to respond to immunotherapy.
Yes. Combination approaches are increasingly common in clinical practice. Immunotherapy is frequently paired with chemotherapy, targeted therapy, or radiation to improve response rates. For instance, combining checkpoint inhibitors with chemotherapy is now a standard first-line approach in certain lung cancer subtypes. Clinical trials continue to explore optimal combinations. Each combination carries its own risk profile, so oncologists assess patient-specific factors carefully before recommending a combined regimen.
